Literature DB >> 2846711

Antibody response of the newborn after herpes simplex virus infection.

J Kahlon1, R J Whitley.   

Abstract

Antibody responses to herpes simplex virus (HSV) types 1 and 2, as determined by enzyme-linked immunoabsorbent assay (ELISA), neutralization, and immunoblot, were assessed in sera from newborns with documented HSV infections. The antibody response of the newborns was defined by disease duration and correlated with disease classification and outcome. Three unique observations were made. First, the quantity of total antibodies at presentation, as determined by ELISA and neutralization, was not predictive of disease classification or outcome. Second, the frequency and intensity of antibody responses to immunologically recognized HSV polypeptides in newborns with central nervous system and disseminated infections were greater than those in newborns with infections localized to the skin, eye, and mouth. Third, the long-term outcome in HSV-infected newborns could be predicted by the quantity of antibodies to the immediate-early infected cell polypeptide ICP 4. These data provide insight into host response to individual polypeptides and their potential value in predicting long-term prognosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846711     DOI: 10.1093/infdis/158.5.925

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Characterisation of the epitope for a herpes simplex virus glycoprotein B-specific monoclonal antibody with high protective capacity.

Authors:  Martin P Däumer; Beate Schneider; Doris M Giesen; Sheriff Aziz; Rolf Kaiser; Bernd Kupfer; Karl E Schneweis; Jens Schneider-Mergener; Ulrich Reineke; Bertfried Matz; Anna M Eis-Hübinger
Journal:  Med Microbiol Immunol       Date:  2010-10-08       Impact factor: 3.402

2.  Toward the rational management of herpes infection in pregnant women and their newborn infants. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1992-05-01       Impact factor: 8.262

3.  Case of the month: a newborn with tachypnoea and consolidation of the right lung.

Authors:  A Karperien; J N van den Anker; P H Rothbarth; R de Groot
Journal:  Eur J Pediatr       Date:  1996-09       Impact factor: 3.183

4.  Application of a transformed cell line constitutively expressing HSV-1 polypeptides for the detection of HSV antibodies in human sera by an enzyme immunoassay.

Authors:  A Sivropoulou; A Vasilaki; M Arsenakis
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

5.  LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase.

Authors:  M P Manns; K J Griffin; K F Sullivan; E F Johnson
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

6.  Isolation and characterization of a recombinant antigen of Pneumocystis carinii.

Authors:  A G Smulian; J R Stringer; M J Linke; P D Walzer
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

7.  Detection of immunoglobulin M antibodies to glycoprotein G-2 by western blot (immunoblot) for diagnosis of initial herpes simplex virus type 2 genital infections.

Authors:  D W Ho; P R Field; W L Irving; D R Packham; A L Cunningham
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

8.  Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection.

Authors:  L H Nguyen; D M Knipe; R W Finberg
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries.

Authors:  P P Sanna; R A Williamson; A De Logu; F E Bloom; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

Review 10.  The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention.

Authors:  Soren Gantt; William J Muller
Journal:  Clin Dev Immunol       Date:  2013-03-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.